Navigation Links
Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
Date:2/1/2011

ROCKVILLE, Md., Feb. 1, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the fourth quarter of 2010, on Thursday, February 10, 2011, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Thursday, February 10, 2011.  Also participating on the call will be James Kelly, Senior Vice President and Chief Financial Officer.  To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.The teleconference dial-in numbers are as follows:Domestic callers 1-800-591-6942International callers 1-617-614-4909Participant Passcode 43128562The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, February 10, 2011, beginning at 1:00 PM ET and will be accessible until Thursday, February 17, 2011, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 66575807.

ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.


'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
2. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
3. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
4. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
6. Vanda Pharmaceuticals Reports First Quarter 2009 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
9. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
10. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
11. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... and ROCKVILLE, Md. , March 24, ... Maxwell Biotech Venture Fund (MBVF), today announced positive results ... to the standard drug therapy regimen in patients with ... molecule drug discovered by scientists at Sequella, Inc. ( ... of Health. A total of 140 ...
(Date:3/24/2017)... March 24, 2017 On Thursday, ... session at 5,817.69, down 0.07%; the Dow Jones Industrial ... the S&P 500 closed at 2,345.96, marginally dropping 0.11%. ... closed in green, 4 sectors finished in red, and ... Stock-Callers.com has initiated reports coverage on the following Biotechnology ...
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
Breaking Biology Technology:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
(Date:2/28/2017)... -- News solutions for biometrics, bag drop and New ... At ... 16 March, Materna will present its complete end-to-end passenger journey, ... a real benefit for passengers. To accelerate the whole passenger ... point solutions to take passengers through the complete integrated process ...
Breaking Biology News(10 mins):